Sana Biotechnology (SANA) Depreciation and Depletion (2020 - 2026)
Sana Biotechnology (SANA) reported Depreciation and Depletion of $2.4 million for Q1 2026, down 34.23% on a YoY basis from $3.6 million in Q1 2025, and down 22.58% sequentially from $3.1 million in Q4 2025.
Sana Biotechnology (SANA) Depreciation and Depletion (2020 - 2026) Analysis & Trends
Sana Biotechnology (SANA) has 7 years of Depreciation and Depletion data on file, last reported at $2.4 million in Q1 2026.
- For the quarter ending Q1 2026, Depreciation and Depletion fell 34.23% year-over-year to $2.4 million; the trailing twelve-month figure through Mar 2026 stood at $11.6 million (down 24.91% YoY), and the FY2025 full-year result was $12.8 million, down 17.42% from the prior year.
- Depreciation and Depletion eased to $2.4 million in Q1 2026, from $3.1 million in the prior quarter.
- In the past five years, Depreciation and Depletion ranged from a high of $4.5 million in Q2 2023 to a low of $2.4 million in Q1 2026.
- A 5-year average of $3.8 million and a median of $3.8 million in 2022 frame the typical range for Depreciation and Depletion.
- Across the five-year window, Depreciation and Depletion soared 60.21% in 2022 and slumped 34.23% in 2026, its largest moves.
- Tracing SANA's Depreciation and Depletion over 5 years: stood at $4.2 million in 2022, then grew by 0.72% to $4.2 million in 2023, then slipped by 9.52% to $3.8 million in 2024, then fell by 18.42% to $3.1 million in 2025, then dropped by 22.58% to $2.4 million in 2026.
- Business Quant data shows SANA's Depreciation and Depletion at $2.4 million in Q1 2026, $3.1 million in Q4 2025, and $3.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation and Depletion (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn | 39.39 Mn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn | - |
| 10 | Sana Biotechnology | 909.47 Mn | 909.47 Mn | - | 2.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.40 Mn |
| Mar 31, 2026 | 2.40 Mn |
| Dec 31, 2025 | 3.10 Mn |
| Dec 31, 2025 | 3.10 Mn |
| Sep 30, 2025 | 3.20 Mn |
| Sep 30, 2025 | 3.20 Mn |
| Jun 30, 2025 | 2.90 Mn |
| Jun 30, 2025 | 2.90 Mn |
| Mar 31, 2025 | 3.65 Mn |
| Mar 31, 2025 | 3.65 Mn |
| Dec 31, 2024 | 3.80 Mn |
| Dec 31, 2024 | 3.80 Mn |
| Sep 30, 2024 | 4.10 Mn |
| Sep 30, 2024 | 4.10 Mn |
| Jun 30, 2024 | 3.90 Mn |
| Jun 30, 2024 | 3.90 Mn |
| Mar 31, 2024 | 3.70 Mn |
| Mar 31, 2024 | 3.70 Mn |
| Dec 31, 2023 | 4.20 Mn |
| Dec 31, 2023 | 4.20 Mn |